Trial Profile
A Phase 1, Placebo-Controlled Study to Determine the Safety, Tolerability and Pharmacokinetics of Escalating Subcutaneous Doses of LJPC-401 in Healthy Adult Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Hepcidin (Primary)
- Indications Iron overload
- Focus Adverse reactions; Pharmacodynamics
- Sponsors La Jolla Pharmaceutical Company
- 17 Jun 2018 Results presented at the 23rd Congress of the European Haematology Association
- 17 May 2018 According to a La Jolla Pharmaceutical Company media release, data from this study will be presented at the European Hematology Association (EHA), June 2018.
- 03 Feb 2017 Status changed from recruiting to completed.